Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 3Tumor-Agnostic 2Thoracic 2Other hematologic neoplasm 2Lymphoid 2Head & Neck 2Gynecologic 2Sarcoma 1Myeloid 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 2Neoplasm Metastasis 1

Interventions

pembrolizumab 46Paclitaxel 46Gemcitabine 41Carboplatin 37Docetaxel 35Bevacizumab 27Cisplatin 25Irinotecan 22Nivolumab 20Fluorouracil 20Erlotinib Hydrochloride 18Pemetrexed 17Capecitabine 17Sorafenib 16Magnetic Resonance Spectroscopy 16Cetuximab 16Afatinib 16Leucovorin 15regorafenib 14olaparib 13Specimen Handling 13Oxaliplatin 13trametinib 12Biopsy 12130-nm albumin-bound paclitaxel 11eribulin 10atezolizumab 10epothilone B 9Radiotherapy 9Midazolam 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × ceralasertib × Tumor-Agnostic × Clear all
NCT02630199 2022-06-15

Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer

Samsung Medical Center

Phase 1 Completed
65 enrolled
Tumor-Agnostic

Neoplasms

NCT03669601 2021-06-04

ATRiUM

Cambridge University Hospitals NHS Foundation Trust

Phase 1 Unknown
55 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡